These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35948327)

  • 1. Correlation of HLA-Cw6 Positivity with Clinical Characteristics and Treatment Efficacy in Korean Patients with Psoriasis.
    Kim SM; Lee H; Lee ES
    Ann Dermatol; 2022 Aug; 34(4):253-260. PubMed ID: 35948327
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Morelli M; Galluzzo M; Madonna S; Scarponi C; Scaglione GL; Galluccio T; Andreani M; Pallotta S; Girolomoni G; Bianchi L; Talamonti M; Albanesi C
    Expert Opin Biol Ther; 2021 Feb; 21(2):259-270. PubMed ID: 33297781
    [No Abstract]   [Full Text] [Related]  

  • 3. Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12/23 blocker, in Chinese patients with psoriasis: a retrospective analysis.
    Chiu HY; Wang TS; Chan CC; Cheng YP; Lin SJ; Tsai TF
    Br J Dermatol; 2014 Nov; 171(5):1181-8. PubMed ID: 24734995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA-Cw6-positive and HLA-Cw6-negative patients with Psoriasis vulgaris have distinct clinical features.
    Gudjónsson JE; Kárason A; Antonsdóttir AA; Rúnarsdóttir EH; Gulcher JR; Stefánsson K; Valdimarsson H
    J Invest Dermatol; 2002 Feb; 118(2):362-5. PubMed ID: 11841557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HLA-Cw6 and psoriasis.
    Chen L; Tsai TF
    Br J Dermatol; 2018 Apr; 178(4):854-862. PubMed ID: 29072309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limited clinical utility of HLA-Cw6 genotyping for outcome prediction in psoriasis patients under ustekinumab therapy: a monocentric, retrospective analysis.
    Anzengruber F; Ghosh A; Maul JT; Drach M; Navarini AA
    Psoriasis (Auckl); 2017; 8():7-11. PubMed ID: 29721444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA-Cw6 increases the risk of psoriasis and early onset before twenty-seven years of age among the Vietnamese population.
    Pham NTU; Nguyen TV; Nguyen HT
    Dermatol Reports; 2024 Jun; 16(2):9854. PubMed ID: 38957641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The HLA-Cw6 Dilemma: Is It Really an Outcome Predictor in Psoriasis Patients under Biologic Therapy? A Monocentric Retrospective Analysis.
    Burlando M; Russo R; Clapasson A; Carmisciano L; Stecca A; Cozzani E; Parodi A
    J Clin Med; 2020 Sep; 9(10):. PubMed ID: 32998429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of the HLA-Cw6 genotype and zinc deficiency in psoriasis vulgaris patients in Indonesia.
    Sangian TY; Waspodo NN; Ilyas F; Djawad K; Seweng A; Tawali S
    Acta Dermatovenerol Alp Pannonica Adriat; 2023 Sep; 32(3):93-97. PubMed ID: 37749969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Consequences of Antibody Formation, Serum Concentrations, and HLA-Cw6 Status in Psoriasis Patients on Ustekinumab.
    De Keyser E; Busard CI; Lanssens S; Meuleman L; Hutten BA; Costanzo A; van den Reek JM; Zweegers J; Lambert J; Spuls PI
    Ther Drug Monit; 2019 Oct; 41(5):634-639. PubMed ID: 31107404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA-Cw6 Status and Treatment Responses Between Psoriasis Patients.
    Temel B; Adisen E; Gonen S
    Indian J Dermatol; 2021; 66(6):632-637. PubMed ID: 35283491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical profile of childhood-onset psoriasis and prevalence of HLA-Cw6: a hospital-based study from India.
    Sathishkumar D; George R; Daniel D; Peter JV
    Postgrad Med J; 2015 Jun; 91(1076):309-14. PubMed ID: 25947201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study.
    Costanzo A; Bianchi L; Flori ML; Malara G; Stingeni L; Bartezaghi M; Carraro L; Castellino G;
    Br J Dermatol; 2018 Nov; 179(5):1072-1080. PubMed ID: 29704432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab.
    Talamonti M; Botti E; Galluzzo M; Teoli M; Spallone G; Bavetta M; Chimenti S; Costanzo A
    Br J Dermatol; 2013 Aug; 169(2):458-63. PubMed ID: 23521149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence that HLA-Cw6 determines early onset of psoriasis, obtained using sequence-specific primers (PCR-SSP).
    Enerbäck C; Martinsson T; Inerot A; Wahlström J; Enlund F; Yhr M; Swanbeck G
    Acta Derm Venereol; 1997 Jul; 77(4):273-6. PubMed ID: 9228217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study of candidate genes for psoriasis near HLA-C in Chinese patients with psoriasis.
    Chang YT; Tsai SF; Lee DD; Shiao YM; Huang CY; Liu HN; Wang WJ; Wong CK
    Br J Dermatol; 2003 Mar; 148(3):418-23. PubMed ID: 12653732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HLA antigens may influence the age of onset of psoriasis and psoriatic arthritis.
    Queiro R; Torre JC; González S; López-Larrea C; Tinturé T; López-Lagunas I
    J Rheumatol; 2003 Mar; 30(3):505-7. PubMed ID: 12610809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic variations in IL6 and IL12B decreasing the risk for psoriasis.
    Boca AN; Talamonti M; Galluzzo M; Botti E; Vesa SC; Chimenti S; Buzoianu AD; Costanzo A
    Immunol Lett; 2013; 156(1-2):127-31. PubMed ID: 24140476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HLA risk haplotype Cw6,DR7,DQA1*0201 and HLA-Cw6 with reference to the clinical picture of psoriasis vulgaris.
    Ikäheimo I; Tiilikainen A; Karvonen J; Silvennoinen-Kassinen S
    Arch Dermatol Res; 1996 Jun; 288(7):363-5. PubMed ID: 8818183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA-Cw6-positive patients with psoriasis show improved response to methotrexate treatment.
    West J; Ogston S; Berg J; Palmer C; Fleming C; Kumar V; Foerster J
    Clin Exp Dermatol; 2017 Aug; 42(6):651-655. PubMed ID: 28512993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.